Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04905082 · ClinicalTrials.gov registry record · NA

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

A NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by City of Hope Medical Center.

Active
Registry status
NA
Development phase
465
Enrollment target
1
Study location

NCT04905082: Active NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by City of Hope Medical Center.

NCT04905082 is a NA study of Malignant Solid Neoplasm and Breast Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 465 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04905082, a NA study of Malignant Solid Neoplasm and Breast Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
465 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. HOPE-Genomics is a web-based education tool that teaches cancer/leukemia patients, and patients who may be at high-risk for developing cancer, about genomic testing and provide patients with information about their own genomic test results. The HOPE-Genomics tool may improve patient's genomic knowledge and quality of patient-centered care. In addition, it may also improve education and care quality for future patients.

Primary Outcome

Recall rate refers to the proportion of patients who accurately remembered whether they had undergone genetic testing, as reported in the 10-day follow-up survey. If a patient's response at the 10-day mark was unavailable, their answer from the 3-month survey was used as a substitute. This metric helps assess how well patients retained and understood information about their genetic testing experience shortly after receiving their results.

Interventions

  • OTHER Survey Administration
  • OTHER Best Practice
  • OTHER Educational Intervention
  • PROCEDURE Genomic Profile

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 465 participants
Start Date 2021-12-30
Est. Completion 2025-12-31
Phase NA
City of Hope Medical Center

582 total trials

What the registry record for NCT04905082 still lists

NCT04905082 is an interventional study that assigns participants to a tested intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (59% lower).

The record links to 7 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.

NCT04905082 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04905082 about?

NCT04905082 is a clinical study titled "HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics". This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. HOPE-Genomics is a web-based education tool that...

What is the current status of trial NCT04905082?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 465 participants. The study started on 2021-12-30. Estimated completion is 2025-12-31.

What conditions does trial NCT04905082 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Breast Carcinoma, Prostate Carcinoma, Colorectal Carcinoma, Lung Carcinoma.

What interventions are being tested in trial NCT04905082?

The interventions under investigation include: Survey Administration (OTHER), Best Practice (OTHER), Educational Intervention (OTHER), Genomic Profile (PROCEDURE).

Who is sponsoring clinical trial NCT04905082?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04905082 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04905082's enrollment target sits among peer trials

465 32nd of 176 higher than 145 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06717698 · 465 participants · Phase 2

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  • NCT07420283 · 465 participants · Phase 2

    A Study of Brenipatide in Participants With Opioid Use Disorder

  • NCT05312879 · 466 participants · Phase 2

    Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

  • NCT06917404 · 466 participants · Phase 3

    A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04905082, the US trial registry maintained by the National Library of Medicine. NCT04905082 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.